156 related articles for article (PubMed ID: 15617027)
1. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
[TBL] [Abstract][Full Text] [Related]
2. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
3. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
4. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Serafin AM; Akudugu JM; Bohm L
Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
[TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
12. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay.
Kinsella P; Clynes M; Amberger-Murphy V
J Neurooncol; 2011 Jan; 101(2):189-98. PubMed ID: 20512610
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
[TBL] [Abstract][Full Text] [Related]
16. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
[TBL] [Abstract][Full Text] [Related]
17. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
18. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
19. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
20. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]